Results 101 to 110 of about 25,871 (216)

Cochlear Implantation in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is a neuroimmunologic demyelinating disorder that may present with central or peripheral sensorineural hearing loss (SNHL). This case describes a 43‐year‐old female with MOGAD and profound right‐sided SNHL who did not improve with neuroimmunologic therapy.
Jacob Mabey   +2 more
wiley   +1 more source

CD39 on CD8+ Tumour‐Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression

open access: yesEuropean Journal of Immunology, Volume 56, Issue 10, October 2026.
On tumour‐reactive CD8+ TILs, CD39 drives two opposing fates at once: It marks cells actively cytolysing tumour cells via released ATP, yet also degrades that same ATP into adenosine, triggering A2AR signalling that locks the cells into a hypoxia‐amplified, self‐reinforcing immunosuppressive loop, blunting their own anti‐tumour action.
Manolo Sambucci   +7 more
wiley   +1 more source

Switch-associated protein 70 (SWAP 70) antibody levels are associated with clinical relapse in multiple sclerosis

open access: yes, 2012
11th International Congress of Neuroimmunology (ISNI) -- NOV 04-08, 2012 -- Boston, MAWOS: 000312764800046…European Sch Neuroimmunol, Int Soc Neuroimmunol ...
Vural, Burcak   +6 more
core  

Neuroimmunology of Stress: Skin Takes Center Stage [PDF]

open access: yes, 2006
Like few other organs, the skin is continuously exposed to multiple exogenous and endogenous stressors. Superimposed on this is the impact of psychological stress on skin physiology and pathology.
Theoharides, Theoharis C.   +12 more
core   +1 more source

RECEPTOR MACHINERY INVOLVED IN MBP-INDUCED ASTROCYTE ACTIVATIONVII International Congress of Neuroimmunology (International Society of Neuroimmunology.

open access: yes, 2004
Our data suggest that MBP interacts with astroglial cells, priming their activation, as proven by HLA class II modulation and HO-1 induction. MBP binding seems to be mediated by LRP,an endocytosis-mediating receptor.
BUSINARO R.   +3 more
core  

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

open access: yesMedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

Rethinking the Oligodendrocyte Progenitor Cell: One Cell, Many Functions

open access: yesEuropean Journal of Neuroscience, Volume 64, Issue 7, October 2026.
Oligodendrocyte progenitor cells (OPCs) are increasingly recognised as multifunctional CNS cells rather than mere precursors of myelinating oligodendrocytes. Alongside myelination and remyelination, they contribute to myelin and circuit plasticity, circuit regulation, vascular and blood–brain barrier regulation and neuroimmune modulation.
Alerie G. de la Fuente
wiley   +1 more source

Mast Cells in Host Defense Against Cutaneous Staphylococcus aureus Infection

open access: yesImmunology &Cell Biology, Volume 104, Issue 9, Page 867-880, October 2026.
Impact of S. aureus epicutaneous sensitization models on mast cell function in vivo. D. farinae and Staphylococcal enterotoxin B (SEB) activate Trpv1+ Tac1+ nociceptors to trigger the release of substance P (SP), which promotes mast cell degranulation through Mrgprb2. S.
Hannah Dychtenberg   +3 more
wiley   +1 more source

Lights On or Off? The Efficacy of Light Therapy as Add‐On to Cognitive Behavioural Therapy for Insomnia—A Pilot Study

open access: yesJournal of Sleep Research, Volume 35, Issue 5, October 2026.
ABSTRACT Cognitive behavioural therapy for insomnia (CBT‐I) is recommended as first‐line treatment for insomnia disorder. However, around 25% of the patients do not respond to the treatment, and only 40% achieve full remission. The current study investigates the therapeutic potential of light therapy as an add‐on to CBT‐I.
Sarah R. Schmid   +9 more
wiley   +1 more source

Patient-derived monoclonal antibodies as a precise molecular tool to understand the pathophysiology of Caspr2-antibody encephalitis [PDF]

open access: yes
Caspr2-antibody encephalitis is a rare yet potentially treatable neurological disorder driven by autoimmunity against the neuronal cell adhesion molecule Caspr2.
Paneva, Sofija
core   +1 more source

Home - About - Disclaimer - Privacy